Ipamorelin
Potential Benefits
- Selective GH release with minimal impact on cortisol and prolactin levels
- May support improved body composition and fat metabolism
- Research suggests potential benefits for bone mineral density
- May promote better sleep quality and recovery
- Generally well-tolerated based on available clinical data
Recommended Starting Dose
100-200 mcg subcutaneously per injection
Based on published research protocols. Not a prescription.
Dosing Protocol
Commonly administered 1-3 times daily at 100-200 mcg per injection, typically before bed and/or upon waking on an empty stomach. Often paired with CJC-1295 (no DAC). Cycles of 8-12 weeks followed by 4-week breaks are typical.
DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.
Expected Timeline
Phase 1
Improved sleep is often reported within the first week. Changes in recovery and body composition typically develop over 6-12 weeks.
Research Status
The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.
Potential Side Effects
- Headache
- Transient flushing
- Mild injection site reactions
- Possible water retention
- Light-headedness shortly after injection
- Rare reports of increased hunger
More in Growth Hormone
CJC-1295 (no DAC) / Mod GRF 1-29
CJC-1295 without DAC
CJC-1295 without DAC (also known as Modified GRF 1-29) is a synthetic growth hormone-releasing hormone (GHRH) analog. It stimulates the pituitary gland to release growth hormone in a pulsatile fashion, mimicking the body's natural rhythm. It is often paired with a GHRP like Ipamorelin for synergistic effects.
CJC-1295 DAC
CJC-1295 with Drug Affinity Complex
CJC-1295 with DAC is a long-acting GHRH analog that includes a Drug Affinity Complex, which binds to albumin in the blood and extends its half-life to approximately 6-8 days. This results in sustained elevation of growth hormone levels rather than pulsatile release. It was developed by ConjuChem Biotechnologies.
Sermorelin
Sermorelin Acetate
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of the naturally occurring 44-amino-acid GHRH molecule. It was previously FDA-approved for diagnosing and treating growth hormone deficiency in children. It stimulates the pituitary to produce and release GH in a natural, pulsatile manner.
Medical Disclaimer
EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.